Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
Antoni Chan MD (Prof) synovialjoints
1 year 10 months ago
Diagnostic work up for sarcoidosis. Think of CVID as an important differential @RheumNow #ACR2024 #sarcoidosis https://t.co/DvJzkN3ZjY
Adela Castro AdelaCastro222
1 year 10 months ago
RA pearls from #ACR24 review course:
1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
2. Multimorbidity=Poor outcomes, High risk for mortality.
3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg
Eric Dein ericdeinmd
1 year 10 months ago
Myths by Daniel Clauw
Small fiber neuropathy - misnomer, non-specific, not worth getting a skin biopsy
Fibromyalgia is not autoimmune - it is nociplastic pain and treated differently
#ACR24 Review Course
@RheumNow https://t.co/JLyfnfMBML
Antoni Chan MD (Prof) synovialjoints
1 year 10 months ago
Pathophysiology of calcinosis. Antonia Valenzuela at Review Course @RheumNow #ACR24 https://t.co/gSJSa2lGXw
TheDaoIndex KDAO2011
1 year 10 months ago
Risk factors and crystal composition of in calcinosis. In SSc - calcinosis is assc with vasculopathy, dz duration #ACR24 #ACRReview https://t.co/LJvrdVG1jg
Dr. John Cush RheumNow
1 year 10 months ago
Infection as a Cause of Death
https://t.co/CwvffN7CcM https://t.co/SwSuAanuEO
Dr. John Cush RheumNow
1 year 10 months ago
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow
1 year 10 months ago
Diagnosis and Management of Kawasaki Disease
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki… https://t.co/rS5bDneplO https://t.co/nZ0GeIQD0T
Antoni Chan MD (Prof) synovialjoints
1 year 10 months ago
Recomendations for the management of Kawasaki’s disease. Cardiometabolic session, Bryce Binstadt @RheumNow #ACR24 https://t.co/KftwMDYzH1
Janet Pope Janetbirdope
1 year 10 months ago
#Baricitinib in refractory #myositis?
A ‘weak’ trial design comparing #Bari to #Bari Rx started 12 weeks later
in a small N =15
neat idea but NO answer
👇
looked like 👍 it worked
BUT
this is not the #RCT design that can show differences
#ACR24 @RheumNow abst#1731
@ACRheum
Dr. John Cush RheumNow
1 year 10 months ago
No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients
UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/XY0UVDTAI6 https://t.co/b09FB3niNP
Jiha Lee JihaRheum
1 year 10 months ago
Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person!
Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse.
@RheumNow https://t.co/NiaUXzt4nT

